Kimberly M Komatsubara1, Richard D Carvajal2. 1. Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Avenue, MHB 6GN-435, New York, NY, 10032, USA. 2. Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Avenue, MHB 6GN-435, New York, NY, 10032, USA. carvajalr@columbia.edu.
Abstract
PURPOSE OF REVIEW: Uveal melanoma is a distinct subset of melanoma with a biology and treatment approach that is unique from that of cutaneous melanoma. Here we will review the current data evaluating immunotherapies in both the adjuvant and metastatic settings in uveal melanoma. RECENT FINDINGS: In the adjuvant setting, interferon demonstrated no survival benefit in uveal melanoma, and studies evaluating immune-based strategies such as vaccine therapy are ongoing. Anti-CTLA-4 and anti-PD-1/ PD-L1 blockade in uveal melanoma have been evaluated in several small prospective and/or retrospective studies with rare responses and no overall survival benefit demonstrated. Ongoing studies evaluating combination checkpoint inhibition and other antibody-based therapies are ongoing. Although immunotherapy with anti-CTLA-4 and anti-PD-1 agents has dramatically changed the treatment approach to cutaneous melanoma, its success in uveal melanoma has been much more limited. Clinical trial participation should be prioritized in patients with uveal melanoma.
PURPOSE OF REVIEW: Uveal melanoma is a distinct subset of melanoma with a biology and treatment approach that is unique from that of cutaneous melanoma. Here we will review the current data evaluating immunotherapies in both the adjuvant and metastatic settings in uveal melanoma. RECENT FINDINGS: In the adjuvant setting, interferon demonstrated no survival benefit in uveal melanoma, and studies evaluating immune-based strategies such as vaccine therapy are ongoing. Anti-CTLA-4 and anti-PD-1/ PD-L1 blockade in uveal melanoma have been evaluated in several small prospective and/or retrospective studies with rare responses and no overall survival benefit demonstrated. Ongoing studies evaluating combination checkpoint inhibition and other antibody-based therapies are ongoing. Although immunotherapy with anti-CTLA-4 and anti-PD-1 agents has dramatically changed the treatment approach to cutaneous melanoma, its success in uveal melanoma has been much more limited. Clinical trial participation should be prioritized in patients with uveal melanoma.
Authors: I W McLean; D Berd; M J Mastrangelo; J A Shields; F H Davidorf; M Grever; T A Makley; J W Gamel Journal: Am J Ophthalmol Date: 1990-11-15 Impact factor: 5.258
Authors: Marcel Martin; Lars Maßhöfer; Petra Temming; Sven Rahmann; Claudia Metz; Norbert Bornfeld; Johannes van de Nes; Ludger Klein-Hitpass; Alan G Hinnebusch; Bernhard Horsthemke; Dietmar R Lohmann; Michael Zeschnigk Journal: Nat Genet Date: 2013-06-23 Impact factor: 38.330
Authors: Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud Journal: Lancet Date: 2014-07-15 Impact factor: 79.321
Authors: Kalijn F Bol; Hanneke W Mensink; Erik H J G Aarntzen; Gerty Schreibelt; Jan E E Keunen; Pierre G Coulie; Annelies de Klein; Cornelis J A Punt; Dion Paridaens; Carl G Figdor; I Jolanda M de Vries Journal: Am J Ophthalmol Date: 2014-07-17 Impact factor: 5.258
Authors: S Leyvraz; S Piperno-Neumann; S Suciu; J F Baurain; M Zdzienicki; A Testori; E Marshall; M Scheulen; T Jouary; S Negrier; J B Vermorken; E Kaempgen; X Durando; D Schadendorf; R Karra Gurunath; U Keilholz Journal: Ann Oncol Date: 2014-02-07 Impact factor: 32.976
Authors: Peter Johansson; Lauren G Aoude; Karin Wadt; William J Glasson; Sunil K Warrier; Alex W Hewitt; Jens Folke Kiilgaard; Steffen Heegaard; Tim Isaacs; Maria Franchina; Christian Ingvar; Tersia Vermeulen; Kevin J Whitehead; Christopher W Schmidt; Jane M Palmer; Judith Symmons; Anne-Marie Gerdes; Göran Jönsson; Nicholas K Hayward Journal: Oncotarget Date: 2016-01-26
Authors: Narges K Tafreshi; Christopher J Tichacek; Darpan N Pandya; Michael L Doligalski; Mikalai M Budzevich; HyunJoo Kil; Nikunj B Bhatt; Nancy D Kock; Jane L Messina; Epifanio E Ruiz; Nella C Delva; Adam Weaver; William R Gibbons; David C Boulware; Nikhil I Khushalani; Ghassan El-Haddad; Pierre L Triozzi; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse Journal: J Nucl Med Date: 2019-02-07 Impact factor: 10.057
Authors: Carin F Gonsalves; David J Eschelman; Robert D Adamo; P Rani Anne; Marlana M Orloff; Mizue Terai; Anthony N Hage; Misung Yi; Inna Chervoneva; Takami Sato Journal: Radiology Date: 2019-08-27 Impact factor: 11.105
Authors: Brian A Boone; Samantha Perkins; Rupal Bandi; Ernesto Santos; Kevin McCluskey; David L Bartlett; James F Pingpank Journal: J Surg Oncol Date: 2018-04 Impact factor: 3.454
Authors: Carlos R Figueiredo; Helen Kalirai; Joseph J Sacco; Ricardo A Azevedo; Andrew Duckworth; Joseph R Slupsky; Judy M Coulson; Sarah E Coupland Journal: J Pathol Date: 2020-04 Impact factor: 7.996